No ODAC for Exelixis thyroid cancer drug; a good sign for cabozantinib?
This article was originally published in Scrip
Executive Summary
Shares of Exelixis gained 5.6% in after-hours trading on 29 August on word the firm's new drug application (NDA) for its experimental thyroid cancer drug cabozantinib would not be the subject of a review by the US FDA’s Oncologic Drugs Advisory Committee (ODAC) in November, when the panel plans to meet over two days.